|
- SGLT2 inhibitors for non-diabetic kidney disease: drugs to . . .
SGLT2 INHIBITORS IMPROVE CV OUTCOMES ALSO IN NON-DIABETIC PATIENTS WITH HF The first large Phase 3 trial of SGLT2 inhibitors enrolling non-diabetic patients in addition to diabetics was the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial
- SGLT2 Inhibitors Use in Non-Diabetic Patients: A Narrative Review
While the SGLT-2 inhibitors are not the drug of choice as the first-line treatment for DM, current research has elucidated that patients with various existing conditions have shown proven benefits on their comorbidities but not on their respective diabetic profiles
- Comparison of Effectiveness Among Different Sodium‐Glucose . . .
In patients with chronic kidney disease, there were no differences in the efficacy outcomes among SGLT2 inhibitors, while in patients without chronic kidney disease, empagliflozin was associated with lower risk of the primary outcome compared with ertugliflozin (HR, 0 77 [95% CI, 0 60–0 98])
- SGLT2 Inhibitors Improve All-Cause and Cardiovascular . . . - AAFP
What effect do sodium-glucose cotransporter-2 (SGLT2) inhibitors have on mortality and cardiovascular and renal outcomes in patients with and without diabetes mellitus, heart failure, or
- SGLT2 Inhibitors’ Cardiovascular Benefits in Individuals . . .
The current evidence supports the potential role of SGLT2 inhibitors as primary prevention in individuals without diabetes, HF, and or CKD This review may shed light on the use of SGLT2 inhibitors in conditions such as stage A HF and metabolic syndrome
- Sodium-glucose cotransporter-2 inhibitors in non-diabetic . . .
In patients with diabetes mellitus treated using SGLT2 inhibitors, increased risk of euglycaemic ketoacidosis has been described in various clinical situations, including in the perioperative setting 1,2 In this context, it remains unclear whether patients without diabetes mellitus treated with SGLT2 inhibitors can also develop euglycaemic keto
- SGLT2 inhibitors: Beyond glycemic control - ScienceDirect
Multiple randomized controlled trials have extensively examined the therapeutic effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors, ushering in a transformative approach to treating individuals with type 2 diabetes mellitus (DM)
|
|
|